Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2013

01-10-2013 | Original Article

The Value of Early Wireless Esophageal pH Monitoring in Diagnosing Functional Heartburn in Refractory Gastroesophageal Reflux Disease

Authors: Eun-Young Park, Myung-Gyu Choi, Meonggi Baeg, Chul-Hyun Lim, Jinsu Kim, Yukyung Cho, Jaemyung Park, Inseok Lee, Sangwoo Kim, Kyuyong Choi

Published in: Digestive Diseases and Sciences | Issue 10/2013

Login to get access

Abstract

Background and Aims

It is difficult to differentiate functional heartburn from proton pump inhibitor (PPI) failure. The aims of this study were to assess the role of early wireless esophageal pH monitoring in patients referred with gastroesophageal reflux disease (GERD) and to identify differences in the clinical spectrum among GERD subtypes.

Methods

We enrolled consecutive referred patients with suspected GERD. After endoscopy on the first visit, all underwent wireless esophageal pH monitoring when off the PPI.

Results

Two hundred thirty patients were enrolled. These patients were classified into a reflux esophagitis group (20, 8.7 %) and a normal endoscopic findings group (210, 91.3 %). Among the 210 patients in the normal endoscopic findings group, 63 (27.4 %) were diagnosed with pathological reflux, 35 (15.2 %) with hypersensitive esophagus, 87 (37.8 %) with normal acid exposure with negative symptom association, and 25 (10.9 %) with test failure. These groups did not differ in age, body mass index, smoking habit, alcohol consumption, symptom severity, quality of life, presence of atypical symptoms, overlap with irritable bowel syndrome, and the frequency of somatization, depression, and anxiety. PPI responses were evaluated in 135 patients. Fifty patients (37.0 %) were not responsive to the 4-week treatment; 26 (19.3 %) were diagnosed with refractory non-erosive gastroesophageal disease, and 24 (17.8 %) with functional heartburn. The demographics and clinical and psychological characteristics did not differ between the two groups.

Conclusions

Demographic characteristics and symptom patterns alone cannot differentiate functional heartburn from various subtypes of GERD. Wireless esophageal pH monitoring should be considered for the initial evaluation of GERD in the tertiary referral setting.
Literature
1.
go back to reference Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61:1340–1354.PubMedCrossRef Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61:1340–1354.PubMedCrossRef
2.
go back to reference Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol. 2010;24:923–936.PubMedCrossRef Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol. 2010;24:923–936.PubMedCrossRef
3.
go back to reference Dickman R, Boaz M, Aizic S, et al. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil. 2011;17:387–394.PubMedCrossRef Dickman R, Boaz M, Aizic S, et al. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil. 2011;17:387–394.PubMedCrossRef
4.
go back to reference Hershcovici T, Fass R. Step-by-step management of refractory gastroesophageal reflux disease. Dis Esophagus. 2013;26:27–36.PubMedCrossRef Hershcovici T, Fass R. Step-by-step management of refractory gastroesophageal reflux disease. Dis Esophagus. 2013;26:27–36.PubMedCrossRef
5.
go back to reference Cho YK, Choi MG, Lim CH, et al. Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness. Scand J Gastroenterol. 2010;45:533–539.PubMedCrossRef Cho YK, Choi MG, Lim CH, et al. Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness. Scand J Gastroenterol. 2010;45:533–539.PubMedCrossRef
6.
go back to reference Hershcovici T, Fass R. Nonerosive reflux disease (NERD)—an update. J Neurogastroenterol Motil. 2010;16:8–21.PubMedCrossRef Hershcovici T, Fass R. Nonerosive reflux disease (NERD)—an update. J Neurogastroenterol Motil. 2010;16:8–21.PubMedCrossRef
7.
go back to reference Lee WC, Yeh YC, Lacy BE, et al. Timely confirmation of gastro-esophageal reflux disease via pH monitoring: estimating budget impact on managed care organizations. Curr Med Res Opin. 2008;24:1317–1327.PubMedCrossRef Lee WC, Yeh YC, Lacy BE, et al. Timely confirmation of gastro-esophageal reflux disease via pH monitoring: estimating budget impact on managed care organizations. Curr Med Res Opin. 2008;24:1317–1327.PubMedCrossRef
8.
go back to reference Fass R. Therapeutic options for refractory gastroesophageal reflux disease. J Gastroenterol Hepatol. 2012;27:3–7.PubMedCrossRef Fass R. Therapeutic options for refractory gastroesophageal reflux disease. J Gastroenterol Hepatol. 2012;27:3–7.PubMedCrossRef
9.
go back to reference van der Velden AW, de Wit NJ, Quartero AO, et al. Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion. 2010;81:43–52.PubMedCrossRef van der Velden AW, de Wit NJ, Quartero AO, et al. Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion. 2010;81:43–52.PubMedCrossRef
10.
go back to reference Frazzoni M, De Micheli E, Zentilin P, et al. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther. 2004;20:81–88.PubMedCrossRef Frazzoni M, De Micheli E, Zentilin P, et al. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther. 2004;20:81–88.PubMedCrossRef
11.
12.
go back to reference Ke MY. How to differentiate non-erosive reflux disease from functional heartburn. J Dig Dis. 2012;13:605–608.PubMedCrossRef Ke MY. How to differentiate non-erosive reflux disease from functional heartburn. J Dig Dis. 2012;13:605–608.PubMedCrossRef
13.
go back to reference Azzam R, Sallum R, Brandao J, et al. Comparative study of two modes of gastroesophageal reflux measuring: conventional esophageal pH monitoring and wireless pH monitoring. Arq Gastroenterol. 2012;49:107–112.PubMedCrossRef Azzam R, Sallum R, Brandao J, et al. Comparative study of two modes of gastroesophageal reflux measuring: conventional esophageal pH monitoring and wireless pH monitoring. Arq Gastroenterol. 2012;49:107–112.PubMedCrossRef
14.
go back to reference Ang D, Teo EK, Ang TL, et al. To Bravo or not? A comparison of wireless esophageal pH monitoring and conventional pH catheter to evaluate non-erosive gastroesophageal reflux disease in a multiracial Asian cohort. J Dig Dis. 2010;11:19–27.PubMedCrossRef Ang D, Teo EK, Ang TL, et al. To Bravo or not? A comparison of wireless esophageal pH monitoring and conventional pH catheter to evaluate non-erosive gastroesophageal reflux disease in a multiracial Asian cohort. J Dig Dis. 2010;11:19–27.PubMedCrossRef
15.
go back to reference Roman S, Mion F, Zerbib F, et al. Wireless pH capsule–yield in clinical practice. Endoscopy. 2012;44:270–276.PubMedCrossRef Roman S, Mion F, Zerbib F, et al. Wireless pH capsule–yield in clinical practice. Endoscopy. 2012;44:270–276.PubMedCrossRef
16.
go back to reference Wenner J, Johnsson F, Johansson J, et al. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol. 2007;102:239–245.PubMedCrossRef Wenner J, Johnsson F, Johansson J, et al. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol. 2007;102:239–245.PubMedCrossRef
17.
go back to reference Ang D, Teo EK, Ang TL, et al. To Bravo or not? A comparison of wireless esophageal pH monitoring and conventional pH catheter to evaluate non-erosive gastroesophageal reflux disease in a multiracial Asian cohort. J Dig Dis. 2010;11:19–27.PubMedCrossRef Ang D, Teo EK, Ang TL, et al. To Bravo or not? A comparison of wireless esophageal pH monitoring and conventional pH catheter to evaluate non-erosive gastroesophageal reflux disease in a multiracial Asian cohort. J Dig Dis. 2010;11:19–27.PubMedCrossRef
18.
go back to reference de Hoyos A, Esparza EA. Technical problems produced by the Bravo pH test in nonerosive reflux disease patients. World J Gastroenterol. 2010;16:3183–3186.PubMedCrossRef de Hoyos A, Esparza EA. Technical problems produced by the Bravo pH test in nonerosive reflux disease patients. World J Gastroenterol. 2010;16:3183–3186.PubMedCrossRef
19.
go back to reference Sweis R, Fox M, Anggiansah A, et al. Prolonged, wireless pH-studies have a high diagnostic yield in patients with reflux symptoms and negative 24-h catheter-based pH-studies. Neurogastroenterol Motil. 2011;23:419–426.PubMedCrossRef Sweis R, Fox M, Anggiansah A, et al. Prolonged, wireless pH-studies have a high diagnostic yield in patients with reflux symptoms and negative 24-h catheter-based pH-studies. Neurogastroenterol Motil. 2011;23:419–426.PubMedCrossRef
20.
go back to reference Sweis R, Fox M, Anggiansah R, et al. Patient acceptance and clinical impact of Bravo monitoring in patients with previous failed catheter-based studies. Aliment Pharmacol Ther. 2009;29:669–676.PubMedCrossRef Sweis R, Fox M, Anggiansah R, et al. Patient acceptance and clinical impact of Bravo monitoring in patients with previous failed catheter-based studies. Aliment Pharmacol Ther. 2009;29:669–676.PubMedCrossRef
21.
go back to reference Martinez S, Malagon I, Garewal H, et al. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537–545.PubMedCrossRef Martinez S, Malagon I, Garewal H, et al. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537–545.PubMedCrossRef
22.
go back to reference Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:1360–1366.PubMedCrossRef Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:1360–1366.PubMedCrossRef
23.
go back to reference de Leone A, Tonini M, Dominici P, et al. The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration. Dig Liver Dis. 2010;42:785–790.PubMedCrossRef de Leone A, Tonini M, Dominici P, et al. The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration. Dig Liver Dis. 2010;42:785–790.PubMedCrossRef
24.
go back to reference Lee JS. Is wireless capsule pH monitoring better than catheter systems? J Neurogastroenterol Motil. 2012;18:117–119.PubMedCrossRef Lee JS. Is wireless capsule pH monitoring better than catheter systems? J Neurogastroenterol Motil. 2012;18:117–119.PubMedCrossRef
25.
go back to reference Cabrera J, Davis M, Horn D, et al. Esophageal pH monitoring with the BRAVO capsule: experience in a single tertiary medical center. J Pediatr Gastroenterol Nutr. 2011;53:404–408.PubMed Cabrera J, Davis M, Horn D, et al. Esophageal pH monitoring with the BRAVO capsule: experience in a single tertiary medical center. J Pediatr Gastroenterol Nutr. 2011;53:404–408.PubMed
26.
go back to reference Lacy BE, Weiser K, Chertoff J, et al. The diagnosis of gastroesophageal reflux disease. Am J Med. 2010;123:583–592.PubMedCrossRef Lacy BE, Weiser K, Chertoff J, et al. The diagnosis of gastroesophageal reflux disease. Am J Med. 2010;123:583–592.PubMedCrossRef
27.
go back to reference Karamanolis G, Kotsalidis G, Triantafyllou K, et al. Yield of combined impedance-pH monitoring for refractory reflux symptoms in clinical practice. J Neurogastroenterol Motil. 2011;17:158–163.PubMedCrossRef Karamanolis G, Kotsalidis G, Triantafyllou K, et al. Yield of combined impedance-pH monitoring for refractory reflux symptoms in clinical practice. J Neurogastroenterol Motil. 2011;17:158–163.PubMedCrossRef
28.
go back to reference Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668–685.PubMedCrossRef Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668–685.PubMedCrossRef
29.
go back to reference Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273–1283.PubMedCrossRef Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273–1283.PubMedCrossRef
30.
go back to reference Kusano M, Hongo M, Miwa H. Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks. Digestion. 2012;85:282–287.PubMedCrossRef Kusano M, Hongo M, Miwa H. Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks. Digestion. 2012;85:282–287.PubMedCrossRef
31.
go back to reference Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: “on” or “off” proton pump inhibitor? Am J Gastroenterol. 2008;103:2446–2453.PubMedCrossRef Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: “on” or “off” proton pump inhibitor? Am J Gastroenterol. 2008;103:2446–2453.PubMedCrossRef
32.
go back to reference Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut. 2012;61:501–506.PubMedCrossRef Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut. 2012;61:501–506.PubMedCrossRef
33.
go back to reference Savarino E, Marabotto E, Zentilin P, et al. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis. 2011;43:542–547.PubMedCrossRef Savarino E, Marabotto E, Zentilin P, et al. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis. 2011;43:542–547.PubMedCrossRef
Metadata
Title
The Value of Early Wireless Esophageal pH Monitoring in Diagnosing Functional Heartburn in Refractory Gastroesophageal Reflux Disease
Authors
Eun-Young Park
Myung-Gyu Choi
Meonggi Baeg
Chul-Hyun Lim
Jinsu Kim
Yukyung Cho
Jaemyung Park
Inseok Lee
Sangwoo Kim
Kyuyong Choi
Publication date
01-10-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2728-4

Other articles of this Issue 10/2013

Digestive Diseases and Sciences 10/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.